Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
hereditary angieoedema
Biotech
Pharvaris runs tox test to reverse clinical hold for HAE asset
Pharvaris' PHA121 will undergo a six-month animal toxicity trial aimed at assuaging concerns over the med’s safety.
Ben Adams
Jan 9, 2023 10:42am
Catabasis Pharmaceuticals no more: Meet Astria Therapeutics
Sep 8, 2021 9:00am
KalVista hit with a clinical hold on 2nd asset
Apr 20, 2021 8:05am
Ionis' antisense drug curbs HAE attacks in phase 2
Mar 29, 2021 9:55am
Pharvaris nabs Shire exec as new CMO
Feb 7, 2020 9:22am
Pharvaris raises $66M to push oral HAE drug through the clinic
Sep 10, 2019 11:08am